Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Publication in refereed journal


Times Cited
Web of Science477WOS source URL (as at 24/11/2020) Click here for the latest count
Altmetrics Information
.

Other information
AbstractBackground The irreversible ErbB family blocker afatinib and the reversible EGFR tyrosine kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation-positive non-small-cell lung cancer (NSCLC). We aimed to compare the efficacy and safety of afatinib and gefitinib in this setting.
All Author(s) ListPark K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JCH, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kolbeck AK, Laurie SA, Tsai CM, Shahidi M, Kim M, Massey D, Zazulina V, Paz-Ares L
Journal nameLancet Oncology
Year2016
Month5
Day1
Volume Number17
Issue Number5
PublisherELSEVIER SCIENCE INC
Pages577 - 589
ISSN1470-2045
eISSN1474-5488
LanguagesEnglish-United Kingdom
Web of Science Subject CategoriesOncology

Last updated on 2020-25-11 at 00:39